A Phase III, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushing's disease

ID Number 14-1411

Principal Investigator(s)
Eliza B Geer

Department(s) or Division(s)


The purpose of this study is to confirm the effectiveness and safety of LCI699 in treating patients with Cushing's disease.

Contact Information
Yelena Lalazar
(212) 241-2613

Recruiting Patients: Yes